Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 20/20 | 1.00 |
| ▸ | ADORA1 | P30542 | 20/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.67 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4452012 | 0.89 | ADORA2A (1.00) | ADORA2AADORA1ADORA3ADORA2B | |
| SCHEMBL4452812 | 0.88 | ADORA2A (1.00) | ADORA2AADORA1ADORA3ADORA2B | |
| SCHEMBL4452784 | 0.87 | ADORA2A (1.00) | ADORA2AADORA1 | |
| SCHEMBL4452773 | 0.85 | ADORA2A (0.73) | ADORA2AADORA1ADORA3ADORA2B | |
| SCHEMBL4452013 | 0.84 | ADORA2A (1.00) | ADORA2AADORA1 | |
| SCHEMBL4459531 | 0.83 | ADORA2A (1.00) | ADORA2AADORA1ADORA3ADORA2B | |
| SCHEMBL4459074 | 0.83 | ADORA2A (1.00) | ADORA2AADORA1ADORA3ADORA2B | |
| SCHEMBL4366004 | 0.81 | ADORA2A (1.00) | ADORA2AADORA1ADORA3ADORA2B | |
| SCHEMBL4462301 | 0.81 | ADORA2A (0.70) | ADORA2AADORA1 | |
| SCHEMBL4046576 | 0.80 | ADORA2A (1.00) | ADORA2AADORA1ADORA3ADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7629349-B2 | Pyrazolo [3,4-d] pyrimidine derivatives and their use as purinergic receptor antagonists | VERNALIS RESEARCH LIMITED (GB) | 2009-12-08 | — | — | US | claimed |
| EP-1349552-B1 | PYRAZOLO[3,4-d]PYRIMIDINE DERIVATIVES AND THEIR USE AS PURINERGIC RECEPTOR ANTAGONISTS | VERNALIS RES LTD (GB) | 2008-08-20 | — | — | EP | claimed |
| US-7087754-B2 | Pyrazolo[3,4-d]pyrimidine derivatives and their use as purinergic receptor antagonists | VERNALIS RESEARCH LIMITED (GB) | 2006-08-08 | — | — | US | claimed |
| US-20060111373-A1 | PYRAZOLO [3,4-D] PYRIMIDINE DERIVATIVES AND THEIR USE AS PURINERGIC RECEPTOR ANTAGONISTS | VERNALIS RESEARCH LIMITED | 2006-05-25 | — | — | US | claimed |
| US-20040116447-A1 | Pyrazolo[3,4-d]pyrimidine derivatives and their use as purinergic receptor antagonists | VERNALIS RESEARCH LIMITED (GB) | 2004-06-17 | — | — | US | claimed |
| US-20210137930-A1 | EXPANSION OF TUMOR INFILTRATING LYMPHOCYTES (TILS) WITH ADENOSINE A2A RECEPTOR ANTAGONISTS AND THERAPEUTIC COMBINATIONS OF TILS AND ADENOSINE A2A RECEPTOR ANTAGONISTS | IOVANCE BIOTHERAPEUTICS, INC. (US) | 2021-05-13 | — | — | US | disclosed |
| US-7629349-B2 | Pyrazolo [3,4-d] pyrimidine derivatives and their use as purinergic receptor antagonists | VERNALIS RESEARCH LIMITED (GB) | 2009-12-08 | — | — | US | disclosed |
| US-7629349-B2 | Pyrazolo [3,4-d] pyrimidine derivatives and their use as purinergic receptor antagonists | VERNALIS RESEARCH LIMITED (GB) | 2009-12-08 | — | — | US | disclosed |
| US-7629349-B2 | Pyrazolo [3,4-d] pyrimidine derivatives and their use as purinergic receptor antagonists | VERNALIS RESEARCH LIMITED (GB) | 2009-12-08 | — | — | US | disclosed |
| EP-1349552-B1 | PYRAZOLO[3,4-d]PYRIMIDINE DERIVATIVES AND THEIR USE AS PURINERGIC RECEPTOR ANTAGONISTS | VERNALIS RES LTD (GB) | 2008-08-20 | — | — | EP | disclosed |
| US-7087754-B2 | Pyrazolo[3,4-d]pyrimidine derivatives and their use as purinergic receptor antagonists | VERNALIS RESEARCH LIMITED (GB) | 2006-08-08 | — | — | US | disclosed |
| US-20060111373-A1 | PYRAZOLO [3,4-D] PYRIMIDINE DERIVATIVES AND THEIR USE AS PURINERGIC RECEPTOR ANTAGONISTS | VERNALIS RESEARCH LIMITED | 2006-05-25 | — | — | US | disclosed |
| US-20040116447-A1 | Pyrazolo[3,4-d]pyrimidine derivatives and their use as purinergic receptor antagonists | VERNALIS RESEARCH LIMITED (GB) | 2004-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060111373-A1 | PYRAZOLO [3,4-D] PYRIMIDINE DERIVATIVES AND THEIR USE AS PURINERGIC RECEPTOR ANTAGONISTS | CHRNA6, CHRNA5, CNR1 | ADORA2A 6/4885ADORA1 15/4885ADORA3 7/4885 |
| US-20210137930-A1 | EXPANSION OF TUMOR INFILTRATING LYMPHOCYTES (TILS) WITH ADENOSINE A2A RECEPTOR ANTAGONISTS AND THERAPEUTIC COMBINATIONS OF TILS AND ADENOSINE A2A RECEPTOR ANTAGONISTS | ADORA2A, ADORA1, CXCR5 | ADORA2A 1/4885ADORA1 2/4885ADORA3 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.